ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Celastrol protects against cisplatin-induced ovarian toxicity via modulation of PPAR-γ and AMPK.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Celastrol (CELA) is a naturally occurring pentacyclic nortriterpenoid quinone found in Tripterygium wilfordii with diverse pharmacological activities. A major and constrictive adverse effect of cisplatin (CIS) is ovarian insufficiency, which affects both the reproductive and non-reproductive health. Current study investigated the ability of CELA to protect against CIS-induced ovarian toxicity in rats. Animals received CELA (0.5 and 1 mg/kg; orally) for 17 consecutive days and CIS (6.0 mg/kg; i.p.) on the 7th and 14th day of the study. CIS induced overt ovarian toxicity as indicated biochemically and histopathologically. CELA protected against CIS-induced reduction in the relative ovarian weight and serum levels of estradiol and anti-mullerian hormones. Co-treatment with CELA prevented the histopathological alterations in ovarian tissues and enhanced the fraction of healthy follicles. Further, it significantly ameliorated CIS-induced lipid peroxidation & antioxidant enzyme exhaustion and inhibited the rise in the expression of the inflammatory markers; tumor necrosis factor-α, cyclooxygenase-2, inducible nitric oxide synthase, and nuclear factor kappa B. This was associated with modulation of Bax and Bcl-2 mRNA expression in favor of inhibition of apoptosis. Notably, co-treatment with CELA prevented CIS-induced reduction in both peroxisome proliferators-activated receptor-γ (PPAR-γ) and phospho-AMP-activated protein kinase (p-AMPK) content. In conclusion, CELA protects against CIS-induced ovarian toxicity in rats. This may be attributed, at least partly, to its antioxidant, anti-inflammatory, and anti-apoptotic activities in addition to enhancement of PPAR-γ and p-AMPK expression in ovarian tissues.
Indexed as
Identifiers
40481255What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.